However, in CY 2027 and later years of Table 166 of this final rule with comment period, the savings estimates also include the impact of this policy on reducing Medicare Advantage payments starting in CY 2027, and this is why the estimates in Table 111 of the CY 2026 OPPS/ASC proposed rule were greater than the commenter's estimates beginning in CY 2027
A GLP-1 blocker acts by inhibiting the GLP-1 receptor, which modulates the downstream inflammatory pathways linked to: cytokine production immune system activation oxidative stress inflammatory signaling in tissues such as the liver, fat cells, and gut In low doses, blocking GLP-1 receptors appears to influence the immune system without significantly interfering with glucose control which is why this approach is being studied specifically for inflammation rather than metabolic disease
ENERGY We could all use a little boost sometimes
K.DennisE
They also tend to show up in a DEXA scan rather than a mirror, which is why most women don't connect the symptoms to the weight loss until something more dramatic - a fracture from a minor fall, for example - forces the issue
We could also see a slowing demand for the obstructive sleep apnea market, which includes a range of products such as continuous positive airway pressure (CPAP) devices